No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

Authors
Publication date
21 May 2020
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Ezid

    redirect
    oaiark:/13030/qt89q9c8dt
    Last time updated on 09/08/2020